Can 3D-Printed models unlock personalized blood cancer therapies?
NCT ID NCT07759661
First seen Aug 12, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study aims to create 3D models of B-cell cancers—like chronic lymphocytic leukemia, splenic marginal-zone lymphoma, and hairy cell leukemia—using blood samples from patients. The goal is to build realistic models that mimic the tumor environment, which could help researchers test and personalize treatments. Adults with these conditions who are receiving standard care may participate by donating extra blood during routine draws.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Patient-derived 3D bioprinted models
- What this could lead to
- If successful, this could lead to more personalized and effective treatments for B-cell cancers like CLL, SMZL, and HCL.
- What could go wrong
- This is an early-stage laboratory study, so the models may not perfectly mimic real patient responses, and results may not directly translate to new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Ospedale San Raffaele
Milan, MI, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a protein blocker quiet Leukemia's alarm system?
- Supercharged immune cells take aim at cancer and viruses in one shot
- Leukemia drug study probes thinking and memory side effects
- Smart blood pressure cuffs could protect cancer patients from heart risks
- New drug duo targets hard-to-treat lymphoma
- New drug takes aim at Hard-to-Treat blood cancers